Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

Inclusion Criteria:

• Participant has histologically confirmed locally advanced/metastatic (stageIIIB/IIIC or IV)

• Participant has a KRAS G12C mutation present in tumor tissue or plasma prior toenrollment, as determined by a Novartis designated central laboratory or by acceptedlocal tests.

• Participants has received one prior platinum-based chemotherapy regimen and oneprior immune checkpoint inhibitor therapy for locally advanced or metastatic disease

• Participant has at least 1 evaluable (measurable or non-measurable) lesion by RECIST 1.1 at the screening visit.

Exclusion Criteria:

• Participants who have previously received docetaxel (except if received inneoadjuvant or adjuvant setting with no progression within 12 months after the ofend of treatment), or any other KRAS G12C inhibitor.

• Participant has EGFR-sensitizing mutation and/or ALK rearrangement by locallaboratory testing. Participants with other druggable alterations will be excludedif required by local guidelines.

• Participant has known active central nervous system (CNS) metastases and/orcarcinomatous meningitis

• Participant has an history of interstitial lung disease or pneumonitis grade > 1.

Other inclusion/exclusion criteria may apply